Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이동현 | - |
dc.date.accessioned | 2021-06-11T16:31:35Z | - |
dc.date.available | 2021-06-11T16:31:35Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 1178-6930 | - |
dc.identifier.other | OAK-29280 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/257716 | - |
dc.description.abstract | Purpose: To investigate the prognostic value of programmed death ligand-1 (PD-L1) expression in tumor-infiltrating immune cells (ICs) in men treated with adjuvant chemotherapy (AC) following radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). Materials and Methods: We retrospectively reviewed 219 "high-risk" (>= pT3a and/or pN+) patients who underwent RC and received cisplatin-based AC for MIBC between March 2015 and September 2019. PD-L1 expression was measured using the VENTANA (SP-142) immunohistochemistry assay and categorized into the three groups according to the percentage of the tumor area covered by PD-L1 expression on ICs: ICO (<1%), IC1 (>= 1% and <5%), and IC2/3 (>= 5%). Positive PD-L1 expression was defined as IC2/3 (>= 5%). Kaplan-Meier survival analysis was used to assess recurrence-free survival (RFS), and Cox proportional hazard models were applied to identify factors predicting tumor recurrence. Results: In the entire cohort, the overall prevalence of PD-L1 IC0, IC1, and IC2/3 was 13.2%, 27.4%, and 59.4%, respectively. During the mean follow-up of 32.5 months, tumor recurrence was detected in 115 (52.5%) patients. On multivariable analysis, tumor stage (>= pT3, P=0.032), positive lymph nodes (P=0.001), and positive PD-L1 on ICs (P=0.005) were independent predictors of tumor recurrence. The 3 year RFS was 54.7% in patients with negative PD-L1 and 31.7% in patients with positive PD-L1. Conclusion: PD-L1 is widely expressed in ICs. Positive PD-L1 on ICs was significantly associated with shorter RFS in patients treated with cisplatin-based AC following RC. The present results support the use of adjuvant immunotherapy in "high-risk" patients with PD-L1-expressing ICs. | - |
dc.language | English | - |
dc.publisher | DOVE MEDICAL PRESS LTD | - |
dc.subject | adjuvant chemotherapy | - |
dc.subject | bladder cancer | - |
dc.subject | programmed death ligand-1 | - |
dc.subject | recurrence | - |
dc.subject | tumor-infiltrating immune cell | - |
dc.title | Prognostic Value of Programmed Death Ligand-1 Expression on Tumor-Infiltrating Immune Cells in Patients Treated with Cisplatin-Based Combination Adjuvant Chemotherapy Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study | - |
dc.type | Article | - |
dc.relation.volume | 14 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.startpage | 845 | - |
dc.relation.lastpage | 855 | - |
dc.relation.journaltitle | ONCOTARGETS AND THERAPY | - |
dc.identifier.doi | 10.2147/OTT.S291327 | - |
dc.identifier.wosid | WOS:000615733300001 | - |
dc.author.google | Lee, Dong Hyeon | - |
dc.author.google | Jeong, Jae Yong | - |
dc.author.google | Song, Wan | - |
dc.contributor.scopusid | 이동현(24341048900;57202299352) | - |
dc.date.modifydate | 20230331134421 | - |